LENZ LENZ THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, LENZ THERAPEUTICS INC reported revenue of $5.49M (up 9.7% from a year earlier), net income of −$31.9M and diluted EPS of −$1.02; over the last four quarters revenue was $21.5M and net income −$126M; for the fiscal year ended December 2025 revenue was $19.1M.
LENZ annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $19.1M, gross profit n/a, operating income −$91.1M, net income −$82.1M (margin -430.3%), EPS −$2.85
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$58.6M, net income −$49.8M (margin n/a), EPS −$2.34
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$72.4M, net income −$70.0M (margin n/a), EPS −$35.71
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$106M, net income −$101M (margin n/a), EPS −$1.84
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$60.4M, net income −$70.8M (margin n/a), EPS −$2.45
LENZ quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $5.49M (up 9.7% year over year), net income −$31.9M, EPS −$1.02
- Quarter ended Mar 31, 2026: revenue $1.90M, net income −$41.5M, EPS −$1.32
- Quarter ended Dec 31, 2025 (from the annual report): revenue $1.59M, net income −$35.9M, EPS −$1.20
- Quarter ended Sep 30, 2025: revenue $12.5M, net income −$16.7M, EPS −$0.59
- Quarter ended Jun 30, 2025: revenue $5.00M, net income −$14.9M, EPS −$0.53
- Quarter ended Mar 31, 2025: revenue $0, net income −$14.6M, EPS −$0.53
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$12.7M, EPS $1.97
- Quarter ended Sep 30, 2024: revenue $0, net income −$10.2M, EPS −$0.38
- Quarter ended Jun 30, 2024: revenue $0, net income −$10.3M, EPS −$0.40
- Quarter ended Mar 31, 2024: revenue n/a, net income −$16.6M, EPS −$3.53
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$23.7M, EPS −$12.06
- Quarter ended Sep 30, 2023: revenue n/a, net income −$18.9M, EPS −$9.62
- Quarter ended Jun 30, 2023: revenue n/a, net income −$14.7M, EPS −$7.53
- Quarter ended Mar 31, 2023: revenue n/a, net income −$12.7M, EPS −$6.50
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$24.6M, EPS −$0.43
- Quarter ended Sep 30, 2022: revenue n/a, net income −$24.7M, EPS −$0.45
- Quarter ended Jun 30, 2022: revenue n/a, net income −$25.9M, EPS −$0.48
- Quarter ended Mar 31, 2022: revenue n/a, net income −$25.8M, EPS −$0.48
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$18.9M, EPS $7.03
- Quarter ended Sep 30, 2021: revenue n/a, net income −$14.6M, EPS −$0.28
LENZ cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$69.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$59.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$60.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$88.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$52.9M, share buybacks n/a
LENZ balance sheet
- Jun 30, 2026: cash $24.2M, total assets $237M, total liabilities $17.3M, shareholders' equity $219M
- Mar 31, 2026: cash $24.8M, total assets $273M, total liabilities $26.0M, shareholders' equity $246M
- Dec 31, 2025: cash $25.2M, total assets $306M, total liabilities $21.5M, shareholders' equity $284M
- Sep 30, 2025: cash $25.4M, total assets $211M, total liabilities $16.8M, shareholders' equity $194M
- Jun 30, 2025: cash $37.6M, total assets $217M, total liabilities $11.0M, shareholders' equity $206M
- Mar 31, 2025: cash $23.0M, total assets $201M, total liabilities $9.24M, shareholders' equity $192M
- Dec 31, 2024: cash $20.2M, total assets $215M, total liabilities $11.2M, shareholders' equity $204M
- Sep 30, 2024: cash $41.0M, total assets $224M, total liabilities $8.73M, shareholders' equity $215M
What is LENZ's revenue?
LENZ THERAPEUTICS INC reported $21.5M of revenue over its last four quarters, through June 30, 2026.
Is LENZ profitable?
No. LENZ THERAPEUTICS INC lost $126M over the last four quarters.
What is LENZ's EPS?
Diluted earnings per share over the last four quarters were −$4.13; −$1.02 in the latest quarter.